Table 3 Percentage of patients with adverse effects observed in the COMPARZ study
From: Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
ADVERSE EFFECT | PAZOPANIB | SUNITINIB |
|---|---|---|
Fatigue | ||
Any grade | 50% | 63% |
Grade 3–4 | 10% | 17% |
Hand-foot syndrome | ||
Any grade | 29% | 50% |
Grade 3–4 | 6% | 11% |
Stomatitis | ||
Any grade | 14% | 27% |
ALTb | 60% | 43% |
Fatal AEas | 2% | 3% |
Fatal treatment-related AEs | 3 cases | 8 cases |